The Spanish Group of CLL (GELLC), with the cooperation of Janssen, launched the TP53 network initiative (RED53), a multicenter task force aimed to facilitate the TP53 and IGHV mutational analysis to the whole country in a due time. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.